For the roughly 300,000 people worldwide living with Duchenne muscular dystrophy, upper-limb function is often the last remaining form of motor independence once ambulation is lost — making any therapy that preserves arm and hand strength potentially life-altering. A landmark Phase 3 trial now provides the most rigorous clinical evidence to date that a cell-based therapy can meaningfully slow this decline.
The HOPE-3 trial enrolled 106 non-ambulatory participants aged 10 and older across multiple centers, randomizing them 1:1 to intravenous deramiocel — a preparation of allogeneic cardiosphere-derived cells originating from donor heart tissue — or placebo, administered every three months over 12 months. The primary endpoint, total Performance of the Upper Limb 2.0 (PUL2.0) score, showed a statistically significant least-squares mean difference of 4.55 percentage points favoring deramiocel (95% CI: 0.47–8.63; p=0.029). Crucially, the safety profile was comparable to placebo, an important finding for a cell therapy given allogeneic origin concerns. Both cardiac and skeletal muscle endpoints were evaluated, extending prior HOPE-2 signals into confirmatory territory.
This result is clinically meaningful on several fronts. Cardiosphere-derived cells are thought to exert paracrine effects — releasing anti-fibrotic, anti-inflammatory, and pro-regenerative signaling molecules — rather than directly replacing lost muscle. This mechanism sidesteps the fundamental genetic defect (dystrophin absence) yet still modifies disease trajectory, positioning deramiocel as a complementary approach alongside exon-skipping and gene therapy strategies. The 4.55% between-group difference on PUL2.0, while modest in absolute terms, represents preserved function in a population experiencing relentless decline; in late-stage DMD, even stabilization is clinically significant. Key limitations include the relatively small sample (n=106), a 12-month observation window that may underestimate longer-term durability or divergence, and the fact that trial participants were predominantly male as expected in X-linked DMD, limiting generalizability. This Phase 3 confirmation from a top-tier journal positions deramiocel as a serious regulatory candidate and a potential new standard-of-care adjunct in advanced DMD management.